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In this review, we present (1) a brief discussion of
hematopoietic stem cell transplantation (HSCT) for severe
and refractory autoimmune diseases (AIDs) from its
beginning in 1996 through recently initiated prospective
randomized clinical trials; (2) an update (up to July 2009)
of clinical and laboratory outcomes of 23 patients with newly
diagnosed type 1 diabetes mellitus (T1DM), who underwent
autologous HSCT at the Bone Marrow Transplantation Unit of
the Ribeira˜o Preto Medical School, University of Sa˜o Paulo,
Brazil; (3) a discussion of possible mechanisms of action of
HSCT in AIDs, including preliminary laboratory data obtained
from our patients; and (4) a discussion of future perspectives
of stem cell therapy for T1DM and type 2 DM, including the
use of stem cell sources other than adult bone marrow and
the combination of cell therapy with regenerative compounds.
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On the basis of the successful therapy of animals with
autoimmune diseases (AIDs), using high-dose immuno-
suppression plus hematopoietic stem cells (HSC) (auto-
logous or allogeneic), and the observed remission of
concurrent AID in patients treated for hematological
disorders (reviewed in refs. 1–5), the first patients with
isolated AID were a priori treated with HSC transplantation
(HSCT). Since then, more than 1000 patients with severe and
refractory AID have been treated in open-phase I/II trials,5
mostly with autologous HSCT (AHSCT). Between one- and
two-thirds of patients experienced sustained remission
of their disease, mostly neurological disorders (multiple
sclerosis and others), rheumatic disorders (systemic lupus
erythematosus, adult and juvenile rheumatoid arthritis,
systemic sclerosis, vasculitis, and others), and hematological
cytopenias (autoimmune hemolytic anemia, immune-
mediated thrombocytopenic purpura, Evans syndrome, and
others). Relapses and mortality rates varied with type and
status of the disease, and with the intensity of immuno-
suppression used before transplant (myeloablative versus
non-myeloablative conditioning regimens). Currently, pros-
pective randomized clinical trials are being planned or
already underway to test safety and efficacy of AHSCT for
severe and refractory AID, compared with the best available
pharmacological treatment (Table 1). Such a trial for adult
rheumatoid arthritis (ASTIRA) was halted in Europe because
of the lack of patients who were not already involved in other
trials with biological agents.
A number of studies that were conducted after HSCT for
AID suggest that the regenerated immune system is more
immune tolerant with a regulatory phenotype, characterized
by increased numbers of naı¨ve and regulatory T cells, and
more diverse T-cell receptor repertoire diversity.6,7
HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS
After more than 10 years of clinical use of HSCT for severe
and refractory AID, animal studies suggested that this
approach could be beneficial for human type 1 diabetes
mellitus (T1DM). In addition, further support for this
approach was derived from clinical studies in which the
effectiveness of immunosuppression for early-onset T1DM
and the beneficial effects of HSCT in diabetic patients with
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hematological disorders were observed. Specifically, beneficial
effects of HSCT in various AIDs,2–5 and in experimental
models of T1DM,1,8,9 together with low/moderate doses of
immunosuppressive drugs in human T1DM,10–14 were docu-
mented, whereas HSCT in individuals with long-standing
T1DM15 was ineffective, and transfer of T1DM from donor
to recipient in allogeneic HSCT16 was noted.
On the basis of the evidence discussed above, HSCT for
early-onset T1DM was proposed in review articles in 2001
(ref. 17) and 2002 (ref. 18), and a clinical protocol, designed
by investigators at Northwestern University in Chicago, USA
(Richard Burt) and the University of Sa˜o Paulo in Ribeira˜o
Preto, Brazil (Ju´lio Voltarelli and others) was approved by
local and national Institutional Review Boards, permitting
the initiation of this study in 2003 in Brazil.
Since 2003, our research group in Brazil has been
conducting an original study of non-myeloablative AHSCT
in patients with newly diagnosed T1DM. The objective of the
treatment is to stop autoimmune destruction of b-cells with
high-dose immunosuppressive drugs (cyclophosphamide and
rabbit antithymocyte globulin), and to ‘reset’ the deleterious
immunological system with one that is reconstituted by an
AHSCT.19 The rationale for this therapy is to both preserve
residual b-cell mass and to facilitate endogenous mechanisms
of b-cell regeneration. Hematopoietic stem cells probably do
not have the capacity to differentiate into large numbers of
b cells; therefore, these cells are used solely to regenerate a
new immune system that lacks autoreactive memory cells
against pancreatic antigens (see below). The exact mecha-
nisms of action that operate in this treatment are still unclear.
However, it has been suggested that AHSCT may shift the
balance from a destructive immune response to immune
tolerance through clonal exhaustion, regulatory cells, cyto-
kine alterations, and changes in T- or B-cell repertoires.1,2
The procedure of AHSCT consists of several steps from
patient selection through long-term follow-up. Most patients
interested in the study were excluded for not fulfilling
enrollment criteria, especially the required short time period
(6 weeks) between the first diagnosis of T1DM and therapy,
positivity for anti-glutamic acid decarboxylase antibodies, or
a lack of a complete understanding of and compliance with
the study protocol. Patients enrolled in the study underwent
HSC mobilization from the bone marrow, using granulocyte
colony-stimulating factor (10 mcg/day) and cyclophos-
phamide (2 g/m2). Mobilized HSC were collected by leuka-
pheresis, cryopreserved, thawed, and infused unmanipulated
(minimum of 2.0 million/kg) after preconditioning with
cyclophosphamide (200 mg/kg) and rabbit antithymocyte
globulin (4.5 mg/kg). Apart from the diabetic status, all the
treated patients were in good health before transplantation,
which explains in part the low frequency and severity of
adverse effects (see below). This outcome is also explained by
the rapid engraftment of neutrophils (mean of 9 days) and
platelets (mean of 10 days).19,20
The first patient enrolled and treated in December 2003
showed a discouraging response. His insulin requirements
increased progressively up to 12 months following trans-
plantation, when he abandoned follow-up and when his
insulin dose was 250% above baseline. His hemoglobin A1c
level was 11.1% at 12 months and his C-peptide concen-
tration did not increase. A possible cause for this poor
clinical response may have been his very low b-cell reserve,
predicted by the previous diagnosis of diabetic ketoacidosis,
and further impaired by the apoptotic effect of glucocorti-
coids used to prevent rabbit antithymocyte globulin reac-
tions. Considering these possibilities, we decided not to use
glucocorticoids in the conditioning regimen in the following
patients and did not include those with previous diabetic
ketoacidosis.
In July 2009, after a mean follow-up of 36.1 months
(range 12 to 65 months), all but two of the subsequent
22 patients became independent of exogenous insulin, most
of them shortly after being placed on high-dose immuno-
suppression and occasionally even before SC infusion.
Nine patients remained insulin-independent following its
discontinuation for a mean period of 40 months (range from
23 to 59 months; Figure 1). Eleven out of 20 patients had to
resume insulin injections after varying periods of insulin
independence, ranging from 6 to 47 months. Ten of the
subjects required 30–50% of their baseline insulin doses after,
and patient no. 11 was using a higher dose than that needed
before transplantation.
Two patients (nos. 2 and 4) became transiently insulin
independent for 47 months and 43 months, respectively.
After 4 and 2 months of resuming insulin injections at daily
doses of 0.25 IU/kg and 0.20 IU/kg, respectively, we opted to
treat these individuals with sitagliptin at 100 mg/day orally.
Both became completely insulin independent after 2 months
(patient no. 2) and after 1 month (patient no. 4), and both
remained independent of exogenous insulin for 12 months
and 13 months, respectively, (Figure 2). Sitagliptin is a
dipeptidyl peptidase-4 inhibitor, a member of a novel class of
oral antihyperglycemic agents. This medication enhances
meal-stimulated active glucagon-like peptide 1 and glucose-
dependent insulinotropic polypeptide levels, improves mea-
sures of b-cell function, suppresses glucagon levels produced
Table 1 | Randomized clinical trials (ongoing or planned)
testing safety and efficacy of autologous hematopoietic stem
cell transplantation for autoimmune diseases compared with
the best available pharmacological treatment
Disease Name
Region of
the world Control arm
Multiple sclerosis ASTIMS Europe Mitoxantrone
Multiple sclerosis MIST USA, Canada,
Brazil
Best available drugs
Systemic sclerosis ASTIS Europe IV cyclophosphamide
Systemic sclerosis SCOT USA IV cyclophosphamide
Crohn’s disease KISS USA Best available drugs
Crohn’s disease ASTIC Europe Best available drugs
Systemic lupus ASTIL Europe Rituximab
Adapted from refs. 5 and 6.
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by a-cells, and increases b-cell mass in rodent models. It also
inhibits T-cell aggression against b-cells.21–23
The 21st patient presented with previous ketoacidosis, and
the 20th patient received steroids (300 mg hydrocortisone)
along with stem cell infusion to prevent reactions to rabbit
antithymocyte globulin. Neither patient ever became insulin
independent.
There was a statistically significant reduction of mean
hemoglobin A1c levels after transplantation, and all insulin-
independent patients achieved A1c levels of o7% (upper
limit of good glucose control) during follow-up. b-Cell
function was analyzed by measuring the area under the curve
of serum C-peptide levels during the mixed-meal tolerance
test. During the follow-up period, both group of patients,
continuously and transiently insulin independent, showed
a significant elevation of C-peptide levels20 of more than two
times of the mean area under the curve.
In face of the good metabolic results that were obtained,
the adverse effects appeared acceptable. With respect to acute
complications, most patients had febrile neutropenia, nausea,
vomiting, and alopecia due to the immunosuppressive
agents used in the mobilization and conditioning phases of
the protocol. Bilateral pneumonia of unidentified etiology,
requiring supplementary oxygen, responded completely to
broad-spectrum antibiotics in patient nos. 2 and 22. These
were the only severe acute complications of the transplanta-
tion procedure. During long-term follow-up, patient no. 2
presented with Graves’ disease at 3.5 years post-transplanta-
tion, and patient no. 3 developed autoimmune hypothyroid-
ism and transient renal dysfunction due to rhabdomyolysis, a
complication that was successfully treated with levothyroxine.
Patient no. 10 presented with mild transient hypergonado-
tropic hypogonadism at 12 months after transplantation.
These late-onset endocrine abnormalities presented by these
three patients may have been caused by the transplant
procedure itself or may have been part of an autoimmune
polyendocrine syndrome that is frequently associated with
T1DM. Of the 16 enrolled men, 13 had sperm examinations
done before treatment: 11/13 had abnormal sperm morpho-
logy and abnormal motility scores, and 2/13 had low
sperm-cell counts (one patient presented with bilateral
cryptorchidism). During the follow-up, eight patients
presented with oligospermia. Two male patients had children
after transplantation (one of them did not have spermograms
before and after transplantation). There was no mortality.
We are currently performing exhaustive studies of
immunoreconstitution (phenotypic and functional) in the
transplanted patients in order to unravel the mechanisms by
which AHSCT produces clinical benefits in type 1 diabetic
patients. Compared with pretransplant profiles, preliminary
results show that after transplantation there is an increase
in the number of regulatory CD4þCD25þFoxp3þ T cells
and Th2 cytokine-producing cells. In addition, we detected
after AHSCT, profound qualitative and quantitative changes
in T-cell receptor repertoire, as well as alterations in the
expression of pro- and anti-apoptotic genes (Malmegrim,
personal communication). Anti-glutamic acid decarboxylase
autoantibodies decreased in most patients but did not corre-
late with clinical response. Further preliminary data from
our ongoing immune reconstitution studies resemble those
observed in other AIDs after AHSCT.6,7 These results support
the suggested hypothesis that a new and more tolerant
immune system is generated after this treatment, explaining
the reduction of autoimmune destruction of insulin-produ-
cing cells and clinical improvement (mechanism no. 2,
Table 2). Other possible mechanisms by which HSCT may
operate in AID are the specific actions of high-dose immuno-
suppression (mechanism no. 1, Table 2) and/or tissue repair
mediated by transdifferentiation and engraftment of admi-
nistered bone marrow stem cells (mechanism no. 3, Table 2).
However, in the presence of anti-glutamic acid decarboxylase
autoantibodies and without specific immunological reactivity
tests to b-cell antigens, we cannot be sure that our treatment
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Figure 1 | Sustained insulin independence after autologous
hematopoietic stem cell transplantation in nine type 1
diabetic patients. No patient had diabetic ketoacidosis or used
corticosteroids during the transplantation procedure.
DKA, diabetic ketoacidosis.
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Figure 2 | Time-course peak stimulated C-peptide levels,
period free from insulin (blue lines), and period of use of
sitagliptin (box) in patients no. 2 and 4.
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blocks autoimmune attack to endocrine pancreas more
efficiently and for longer time than other immunosuppressive
interventions, particularly anti-T-cell therapies.
Our clinical trial was approved by the National Institu-
tional Review Board and it was registered at http://
clinicaltrials.gov under number NCT00315133.
CONCLUSIONS AND PROSPECTIVE
Type 1 diabetes mellitus
Our preliminary study of AHSCT in a subset of non-
ketoacidotic newly diagnosed T1DM patients yielded a
number of unexpected positive results: 20/21 patients were
able to stop insulin use after initiation of high-dose
immunosuppression, and nine patients maintained this
status after a mean follow-up of 40 months (maximum of
59 months). Ten patients relapsed after stopping insulin use,
and one patient who received steroids during conditioning
never became insulin independent. In this group, two
patients regained insulin independence after treatment
with sitagliptin, which was associated with an increase in
C-peptide levels. Longer follow-up and controlled studies
are needed to evaluate the full potential of this novel therapy
of early T1DM.
The underlying mechanism of action of the various
components of the AHSCT (cyclophosphamide, ATG, and
stem cells) cannot be studied by direct methods in humans;
however, our current immune reconstitution studies and
similar studies in other AIDs suggest that the immune system
is reset toward a tolerant phenotype, as evidenced by
increased regulatory T-cell numbers and by the regeneration
of a different and more diverse T-cell receptor repertoire. We
hypothesize that the combination of high-dose immuno-
suppression and HSC infusions function synergistically
to downregulate autoreactive T cells, to renew the immune
system, and to improve the immune regulatory networks.
Although our approach provides the proof of principle
that high-dose immunosuppression coupled with autologous
HSC boosting can revert early-onset T1DM in humans, it will
hardly solve the overall problem of the disease. First, only a
small subset of patients with early-onset T1DM were
successfully treated with AHSCT, whereas millions of patients
with long-standing T1DM will likely need another type of
stem cell to regenerate pancreatic b-cells and other damaged
tissues. Second, AHSCT is an expensive, cumbersome, and
complex procedure performed in specialized bone marrow
transplantation facilities, and has the potential of causing
life-threatening short- and long-term complications. In the
future, more simple approaches such as pharmacological,
biological, or cellular immunoregulatory interventions may
accomplish the same therapeutic goal in millions of type 1
diabetic patients. Besides HSC, other types of stem cells,
such as embryonic, mesenchymal, or those from umbilical
cord blood, may be promising candidates to fulfill this role
(reviewed in ref. 11). At this point, AHSCT and islet/pancreas
transplantation remain currently the only treatment options
to durably reverse the disease in humans. However, the utility
of AHSCT will have to be tested in other groups of patients
(with previous ketoacidosis, with longer duration of the
disease, and in young children). The potential of incretin
enhancers, such as sitagliptin, to restore insulin indepen-
dence, as observed in two of our patients who relapsed after
HSCT, illustrates the possible role of combination therapies
(stem cells plus immunosuppression plus regenerative
compounds) in the future treatment of T1DM.24
Type 2 diabetes mellitus
Type 2 diabetes mellitus (DM2) is associated with insulin
resistance and secretory dysfunction of the b cells. There are
now experimental, epidemiological, and clinical evidences,
suggesting the involvement of immune system and inflam-
matory mediators in both pathogenic mechanisms of
DM2.25–29 Although the initiating events of b-cells lesion
are different in DM1 and DM2, the final pathway of
pancreatic b-cell death have similarities in DM1 and DM2,
suggesting the potential of immunological and regenerative
interventions in DM2 as well.
Cellular therapy with stem cells for glycemic control has
been tested in experimental models for some years,30–32 and
various sources of stem cells to replace pancreatic b-cells are
now under investigation. However, there are only few studies
of such approaches reported in humans. Estrada et al.33
reported improvements in glycemic control and C-peptide
levels and reduction in insulin requirements in patients with
DM2 submitted to combined therapy of intrapancreatic
autologous stem cell infusion and hyperbaric oxygen therapy.
Bhansali et al.34 reported the same benefits in patients
with DM2 after intra-arterial infusion of autologous bone
marrow-derived stem cells.
Although there are many obstacles to be overcome
before regenerative therapy becomes a real option to treat
DM2, in the future it may become an important strategy to
attain metabolic control and in prevention of chronic
complications.
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